|Dr. Simon N. Pimstone||CEO & Director||679.72k||N/A||1968|
|Mr. Ian C. Mortimer C.M.A., CPA, M.B.A., MBA, CPA, CMA||Pres, CFO, COO & Company Sec.||558.58k||N/A||1976|
|Mr. Ernesto Aycardi-Fonseca M.D.||Chief Medical Officer||609.08k||N/A||1963|
|Mr. Robin P. Sherrington||Exec. VP of Strategy & Innovation||N/A||N/A||1961|
|Dr. James R. Empfield||Sr. VP of Drug Discovery||N/A||N/A||1961|
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in phase I clinical trials. The company was founded in 1996 and is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.